search
Back to results

HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection (HOME-CoV)

Primary Purpose

Coronavirus Infection

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
HOME-CoV rule implementation
Sponsored by
University Hospital, Angers
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronavirus Infection focused on measuring covid-19, outpatient, expert consensus, decision-making

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patient (≥ 18 years old)
  • Admitted for COVID-19 infection confirmed by a positive SARS-CoV2 RT-PCR or considered probable by the physician in charge of the patient.
  • Not requiring care in intensive care unit or resuscitation unit or
  • No subject of a limitation decision of active therapies,
  • Free informed express consent to participate in the study orally given or signed by the patient according to local legislation,
  • Insurance cover according to local legislation;

Exclusion Criteria:

  • Patient whose main diagnostic hypothesis in the emergency room is not a SARS-CoV-2 infection but another differential diagnosis,
  • Patient admitted to the emergency room for 18 hours or more,
  • Patient whose follow-up on D28 is impossible, whatever the reason,
  • Patient with a poor understanding of the French language,
  • Patient already included in the study,
  • Person deprived of their liberty by judicial or administrative decision,
  • Person under psychiatric care under duress,
  • Person subject to a legal protection measure,
  • Person unable to express consent.

Sites / Locations

  • Clinique Universitaire Saint-Luc
  • CHU de Liège
  • Ch Argenteuil
  • CH Cholet
  • CHU Clermont Ferrand
  • Ch Colmar
  • CH Alpes Lemant
  • CHU Dijon
  • CH Le Mans
  • CH Libourne
  • CH Limoges
  • Ch Longjumeau
  • Chu Montpellier
  • Centre Hospitalier Universitaire de Nantes
  • CH Niort
  • Hopital Paris Saint Joseph
  • Hopital Saint Antoine
  • Hôpital Bichat
  • Hôpital Lariboisière
  • CHU de Poitiers
  • CH Reims
  • Ch Remiremont
  • Chu Rennes
  • CHU de Rouen
  • CHU de St Etienne
  • CH de Saint-Brieuc
  • Ch Troyes
  • CH VICHY
  • CH Princesse Grace

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Phase1: Before HOME-CoV rule implementation

Phase 2: After HOME-CoV rule implementation

Arm Description

Observational assessment of current practices: no recommendation is performed. Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants. A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion.

Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision. Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants. A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion.

Outcomes

Primary Outcome Measures

the composite rate of adverse outcomes
Adverse outcomes include intubation with mechanical ventilation requirement and death (Stage ≥ 6 on "Ordinal Scale for Clinical Improvement" of the World Health Organization) within 7 days after inclusion.
The rate of hospitalization
The rate of patients hospitalized after admission to the emergency room including patients discharged home more than 24 hours after admission. It will be analyzed in a hierarchical approach, only if first primary objective is positive i.e. non-inferiority of HOME-CoV strategy versus current practice on the rate of adverse outcomes.

Secondary Outcome Measures

Full Information

First Posted
April 5, 2020
Last Updated
September 22, 2020
Sponsor
University Hospital, Angers
search

1. Study Identification

Unique Protocol Identification Number
NCT04338841
Brief Title
HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection
Acronym
HOME-CoV
Official Title
HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
April 9, 2020 (Actual)
Primary Completion Date
June 17, 2020 (Actual)
Study Completion Date
June 17, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
COVID-19 pandemic has developed worldwide in less than 4 months. The clinical presentations are variable widely, ranging from simple rhinitis to major lung damage that can lead to death. In many countries involved in the ongoing health disaster due to SARS-CoV-2 infection, hospital are overloaded. In this context, the decision to hospitalize or to manage COVID-19 patients at home is crucial and defining reliable and consensual criteria is a major issue. HOME-CoV study is a multicentre quasi-experimental interventional study, before and after implementation of a help-decision making rule (HOME-CoV rule), developed via the Delphi method. Our main hypothesis is that a strategy based on the consensual HOME-CoV rule compared to current practice is at least as safe as regards the 7-day-rate of adverse events (safety criterion) and more effective as regards the rate of patients eventually managed as outpatients (efficacy criterion).
Detailed Description
Definition of HOME-CoV rule: The Delphi method is used to reach a consensus of a large panel of experts and to define an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making : the HOME-CoV rule. The impact of the rule implementation is evaluated in a before and after study: before period: observational assessment of current practices implementation period : educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments. after period : observational assessment of practices In each period, patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants. A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronavirus Infection
Keywords
covid-19, outpatient, expert consensus, decision-making

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Quasi-experimental before and after multicentre prospective study
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
3133 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Phase1: Before HOME-CoV rule implementation
Arm Type
No Intervention
Arm Description
Observational assessment of current practices: no recommendation is performed. Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants. A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion.
Arm Title
Phase 2: After HOME-CoV rule implementation
Arm Type
Experimental
Arm Description
Observational assessment of practices after implementation of the rule: physicians are recommended to apply the HOME-CoV rule but still free to use other determinants in their decision. Patients consulting Emergency Departments with suspected or probable COVID-19 are evaluated for potential inclusion. Clinical, biological and imaging data that may be involved in decision-making about hospitalization are collected as well as the physician final decision (hospitalization or outpatient management) and its main determinants. A phone-call follow-up is performed and the clinical status according to the Ordinal Scale for Clinical Improvement of COVID-19 from the World Heath Organization is collected on day 7 and day 28 following inclusion.
Intervention Type
Other
Intervention Name(s)
HOME-CoV rule implementation
Intervention Description
HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts. Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.
Primary Outcome Measure Information:
Title
the composite rate of adverse outcomes
Description
Adverse outcomes include intubation with mechanical ventilation requirement and death (Stage ≥ 6 on "Ordinal Scale for Clinical Improvement" of the World Health Organization) within 7 days after inclusion.
Time Frame
day 7
Title
The rate of hospitalization
Description
The rate of patients hospitalized after admission to the emergency room including patients discharged home more than 24 hours after admission. It will be analyzed in a hierarchical approach, only if first primary objective is positive i.e. non-inferiority of HOME-CoV strategy versus current practice on the rate of adverse outcomes.
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patient (≥ 18 years old) Admitted for COVID-19 infection confirmed by a positive SARS-CoV2 RT-PCR or considered probable by the physician in charge of the patient. Not requiring care in intensive care unit or resuscitation unit or No subject of a limitation decision of active therapies, Free informed express consent to participate in the study orally given or signed by the patient according to local legislation, Insurance cover according to local legislation; Exclusion Criteria: Patient whose main diagnostic hypothesis in the emergency room is not a SARS-CoV-2 infection but another differential diagnosis, Patient admitted to the emergency room for 18 hours or more, Patient whose follow-up on D28 is impossible, whatever the reason, Patient with a poor understanding of the French language, Patient already included in the study, Person deprived of their liberty by judicial or administrative decision, Person under psychiatric care under duress, Person subject to a legal protection measure, Person unable to express consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Delphine DOUILLET
Organizational Affiliation
University Hospital, Angers
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique Universitaire Saint-Luc
City
Bruxelles
Country
Belgium
Facility Name
CHU de Liège
City
Liege
Country
Belgium
Facility Name
Ch Argenteuil
City
Argenteuil
Country
France
Facility Name
CH Cholet
City
Cholet
Country
France
Facility Name
CHU Clermont Ferrand
City
Clermont Ferrand
Country
France
Facility Name
Ch Colmar
City
Colmar
Country
France
Facility Name
CH Alpes Lemant
City
Contamine-sur-Arve
Country
France
Facility Name
CHU Dijon
City
Dijon
Country
France
Facility Name
CH Le Mans
City
Le Mans
Country
France
Facility Name
CH Libourne
City
Libourne
Country
France
Facility Name
CH Limoges
City
Limoges
Country
France
Facility Name
Ch Longjumeau
City
Longjumeau
Country
France
Facility Name
Chu Montpellier
City
Montpellier
Country
France
Facility Name
Centre Hospitalier Universitaire de Nantes
City
Nantes
Country
France
Facility Name
CH Niort
City
Niort
Country
France
Facility Name
Hopital Paris Saint Joseph
City
Paris
Country
France
Facility Name
Hopital Saint Antoine
City
Paris
Country
France
Facility Name
Hôpital Bichat
City
Paris
Country
France
Facility Name
Hôpital Lariboisière
City
Paris
Country
France
Facility Name
CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Name
CH Reims
City
Reims
Country
France
Facility Name
Ch Remiremont
City
Remiremont
Country
France
Facility Name
Chu Rennes
City
Rennes
Country
France
Facility Name
CHU de Rouen
City
Rouen
Country
France
Facility Name
CHU de St Etienne
City
Saint Etienne
ZIP/Postal Code
42000
Country
France
Facility Name
CH de Saint-Brieuc
City
Saint-Brieuc
Country
France
Facility Name
Ch Troyes
City
Troyes
Country
France
Facility Name
CH VICHY
City
Vichy
Country
France
Facility Name
CH Princesse Grace
City
Monaco
Country
Monaco

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34004154
Citation
Douillet D, Penaloza A, Mahieu R, Morin F, Chauvin A, Gennai S, Schotte T, Montassier E, Thiebaud PC, Ghuysen Francois A, Dall'acqua D, Benhammouda K, Bissokele P, Violeau M, Joly LM, Andrianjafy H, Soulie C, Savary D, Riou J, Roy PM; Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection Study Group. Outpatient Management of Patients With COVID-19: Multicenter Prospective Validation of the Hospitalization or Outpatient Management of Patients With SARS-CoV-2 Infection Rule to Discharge Patients Safely. Chest. 2021 Oct;160(4):1222-1231. doi: 10.1016/j.chest.2021.05.008. Epub 2021 May 15.
Results Reference
derived
PubMed Identifier
32888112
Citation
Douillet D, Mahieu R, Boiveau V, Vandamme YM, Armand A, Morin F, Savary D, Dubee V, Annweiler C, Roy PM; HOME-CoV expert group. Outpatient management or hospitalization of patients with proven or suspected SARS-CoV-2 infection: the HOME-CoV rule. Intern Emerg Med. 2020 Nov;15(8):1525-1531. doi: 10.1007/s11739-020-02483-0. Epub 2020 Sep 4.
Results Reference
derived

Learn more about this trial

HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection

We'll reach out to this number within 24 hrs